ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Innovative wearables offer glimpse into continuous, unobtrusive health monitoring

The recent advances and barriers in the development of wearable sensors.

January 9, 2024

Addressing the “postpartum cliff” may be as simple as a sending few text messages

Most pregnant people are in regular touch with their maternity care providers over the course of nine months, with ever-more-frequent visits, tests, and scans as

July 16, 2024

Asthma Control Better With Biologic-Corticosteroid Combo

WASHINGTON — Adding dupilumab (Dupixent) to a medium-dose inhaled corticosteroid (ICS) routine helped lower asthma exacerbations and improved both lung function and asthma control, according

February 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.